External Oblique and Rectus Abdominis Plane Block Versus Quadratus Lumborum Block for Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy

NCT ID: NCT07082387

Last Updated: 2025-07-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-24

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare the effects of the external oblique and rectus abdominis plane (EXORA) block and the quadratus lumborum block (QLB) on postoperative analgesia in patients undergoing laparoscopic cholecystectomy (LC).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Laparoscopic cholecystectomy (LC) is a proven, gold standard surgical procedure for the management of gallbladder stones.

The quadratus lumborum block (QLB) is a regional block that would appear to be similar to the posterior TAP block, although the drug injection area is deeper and more dorsal than the transverse abdominal aponeurosis.

The external oblique and rectus abdominis plane (EXORA) block is an emerging technique providing a sensory block to the anterolateral abdominal wall.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

External Oblique and Rectus Abdominis Plane Block Quadratus Lumborum Block Postoperative Analgesia Laparoscopic Cholecystectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EXORA group

Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20ml of bupivacaine 0.25%.

Group Type EXPERIMENTAL

External oblique and rectus abdominis plane block

Intervention Type OTHER

Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20ml of bupivacaine 0.25%.

QLB group

Patients will receive a quadratus lumborum block (QLB) using 20ml of bupivacaine 0.25%.

Group Type EXPERIMENTAL

Quadratus lumborum block

Intervention Type OTHER

Patients will receive a quadratus lumborum block (QLB) using 20ml of bupivacaine 0.25%.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

External oblique and rectus abdominis plane block

Patients will receive an external oblique and rectus abdominis plane (EXORA) block using 20ml of bupivacaine 0.25%.

Intervention Type OTHER

Quadratus lumborum block

Patients will receive a quadratus lumborum block (QLB) using 20ml of bupivacaine 0.25%.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 to 65 years.
* Both sexes.
* American Society of Anesthesiology (ASA) physical status I-II.
* Undergoing laparoscopic cholecystectomy (LC) under general anesthesia.

Exclusion Criteria

* History of allergies to local anesthetics.
* Opioid dependency.
* Bleeding or coagulation disorders.
* Psychiatric and neurological disorder.
* Local infection at the site of injection.
* Body mass index (BMI) \> 35.
* Hypertension.
* Uncontrolled diabetes mellitus.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohammed Said ElSharkawy

Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta University

Tanta, El-Gharbia, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mohammed S Elsharkawy, MD

Role: CONTACT

00201148207870

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mohammed S Elsharkawy, MD

Role: primary

00201148207870

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

36264PR1261/6/25

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.